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INTRODUCTION 
Theophylline and its derivatives currently occupy a central role 
in the management of asthma and other forms of chronic obstructive 
lung disease. Unfortunately, theophylline has a relatively narrow 
therapeutic index. Inadequate bronchodilation is frequent with 
serum concentrations less than 10 mcg/ml, whereas toxicity is often 
1 2 
apparent with concentrations greater than 20 mcg/ml. ' A variety 
of toxic reactions, including gastrointestinal disturbances, cardiac 
arrhythmias, and central nervous system alterations occur with in-
creasing frequency as serum concentrations rise progressively above 
20 mcg/ml. ^  
In recent years, a number of factors have been shown to signifi-
cantly alter plasma clearance and thereby alter theophylline serum 
concentrations. Patients who are either in the pediatric age group 
or are smokers have higher theophylline plasma clearances and reduced 
6—8 
serum concentrations. Patients with hepatic cirrhosis, pulmonary 
edema, cor pulmonale, acute viral and bacterial respiratory illness, 
congestive heart failure, acute worsening of obstructive airway 
disease, or elderly patients often have reduced theophylline clear-
9—18 
ances and relatively high serum concentrations. However, even 
in the absence of such factors, there is a large interpatient 
variability in chronic stable asthmatics, presumably due to genetic 
19-22 
and environmental factors. As a result, different patients 
2 
receiving the same dose of theophylline may have either low serum 
concentrations and inadequate drug effect, or high serum concentra-
tions and toxicity. 
A number of drugs also have been reported to alter the dis-
position of theophylline or its metabolites. These drugs include 
23 24 25 phenobarbital, ' allopurinol, and most recently the beta-
26 
blocking agents propranolol and metoprolol. 
A limited number of studies and observations have suggested 
that macrolide antibiotics can also affect the serum concentrations 
of theophylline in patients on chronic theophylline therapy. Weinberger 
27 
et al in 1977 found a mean decrease in theophylline clearance of 50 
percent during administration of troleandomycin. 
However, the studies reporting changes in theophylline disposition 
during administration of the macrolide antibiotic erythromycin are of 
more clinical relevance since erythromycin, not troleandomycin, is 
commonly used at the present time for treatment of various infections. 
The only published prospective study addressing this issue was 
28 
that of Pfeifer et al. The investigators were unable to demonstrate 
an overall significant decrease in clearance of theophylline after 
administration of erythromycin. 
29-31 
The reports of Cummins et al are commonly cited in the litera-
ture as proof of a clinically significant drug interaction between 
theophylline and erythromycin. Their reports, however, were retro-
spective, without controls, and included a limited number of pediatric 
patients. 
3 
The purpose of this project was to conduct a controlled, pro-
spective study to document whether there is a significant change 
in the serum concentration of theophylline after erythromycin 
challenge in elderly patients with chronic obstructive lung disease. 
METHODS 
Study Design 
The study was prospective with each patient serving as his own 
control. It was conducted between the months of September 1980 and 
February 1981. Permission to conduct the study was granted by the 
Human Studies Committee of the Veterans Administration Medical Center 
and the Institutional Review Board of the University of Utah. 
Patient Selection 
The study involved 18 male volunteers whose age ranged from 51 
to 82 years (mean age 65). The subjects were patients in the nursing 
home care unit, long-term care facility, or the medicine wards of 
the Salt Lake Veterans Administration Medical Center. Informed 
written consent was obtained from all patients after they received 
an explanation of the study purpose and protocol by one of the in-
vestigators. A physical examination and medication history were 
obtained on each patient by the investigators. Patients were ad-
mitted to the study after application of the following inclusion 
criteria: 
1) All patients were receiving maintenance theophylline therapy 
for documented chronic obstructive airways disease. 
2) All patients were clinically stable upon admission to and 
throughout the course of the study as assessed by one of the physician 
investigators. 
5 
To minimize intrapatient variability in serum theophylline 
clearance during the course of the study, prospective participants 
were excluded from the study according to the following criteria: 
1) Deterioration of their chronic obstructive airways disease 
at any time during the month prior to entering the study. 
2) Manifestation of symptoms consistent with an upper respiratory 
infection at any time during the month prior to entering the study. 
3) Demonstration of a pneumonic infiltrate on chest X-ray at any 
time during the month prior to entering the study. 
4) Evidence on admission to the study of left- or right-sided 
congestive heart failure with either cardiomegaly or prominence of 
upper lung zone blood vessels on chest X-ray or jugular venous dis-
tention and peripheral edema on physical exam. 
5) Alteration in cigarette consumption by more than 20 cigarettes 
per day during the previous year. 
6) Receipt of medications (phenobarbital, allopurinol, beta-
blockers) known or suspected to interact with theophylline at any time 
during the month prior to entering the study. 
7) Evidence of active liver disease as assessed by elevated liver 
function studies or low serum albumin. 
8) Receipt of erythromycin during the previous month. 
Patients were also excluded if they became clinically unstable 
during the study based on these criteria. All subjects were instructed 
by the investigators to continue their usual xanthine intake, dietary 
habits, and smoking patterns during the course of the study. 
Methodology 
Twelve patients admitted into the study received oral theophyl-
line as aminophylline tablets (Aminophyllin ®, Searle), one patient 
received oxtriphylline tablets (Choledyl®, Warner-Chilcott), and five 
patients received sustained-release theophylline tablets (Theodur®, 
Key Pharmaceuticals).* Patients receiving other brands of aminophyl-
line were changed to that manufactured by Searle due to lack of ade-
quate bioavailability data for other aminophylline products. All 
other medications were maintained without change throughout the study 
period. 
The study was divided into two phases. The patients in Phase I 
received eight doses of erythromycin over two days. The patients in 
Phase II received 28 doses of erythromycin over seven days. Patients 
in Phase II were studied after Phase I had been completed. 
On admission to the study, two baseline serum theophylline 
samples (sample A and B) were collected 48 hours apart prior to admin-
istration of erythromycin to serve as a control value for each patient.** 
The patient was considered to be clinically stable and steady state 
attained if the serum theophylline concentrations from samples A and B 
were within 3 mcg/ml of each other. 
*Aminophyllin ® is 84.6% theophylline. Choledyl®, a coated theo-
phylline preparation, is approximately 64% theophylline. Theodur® is 
a sustained-release preparation which is 100% theophylline. 
**A11 theophylline samples were collected by the investigators 30 
minutes prior to the patient's next scheduled theophylline dose and 
considered to be trough serum theophylline concentrations. Each sample 
was collected into two Venoject® tubes and assayed either immediately 
or at the completion of the study. 
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The eleven patients in Phase I received 500 mg (two 250 mg tablets) 
of erythromycin stearate (Erythrocin®, Abbott) on an empty stomach four 
times a day for 48 hours. A third serum theophylline sample (sample C) 
was collected after all eight doses of erythromycin were administered. 
The seven patients in Phase II had a third serum theophylline 
sample (sample C) collected after four days of erythromycin and a fourth 
serum theophylline sample (sample D) was collected after seven days of 
erythromycin. Figures 1 and 2 are graphic representations of the study 
design. 
Patients were closely monitored by the investigators and nursing 
staff for any adverse reactions while participating in the study. 
Theophylline Assay Procedure 
The samples were collected into Venoject® grey-stoppered vacuum 
tubes, gently inverted several times, maintained in an upright position, 
and immediately centrifuged. The serum was decanted and placed into 
culture tube screw cap vials (14 ml, T1346-4, American Scientific 
Products) having a special teflon-faced rubber liner to minimize 
adsorption of theophylline and ensure more reliable measurements. The 
theophylline assay was then performed by the toxicology laboratory in 
collaboration with the clinical chemistry laboratory at the University 
of Utah Hospital on one of the duplicates in each set while the other 
sample was frozen at -70° C to await grouped analysis at the end of 
the study. Quality control serum theophylline samples were provided 
by the toxicology laboratory and were frozen with the duplicate samples 
8 
awaiting grouped analysis. The theophylline assay performed on the 
samples was the quantitative Enzyme Mediated Immunoassay Technique® 
(EMIT® Syva) for serum theophylline. The advantages of this technique 
are its specificity, requirement of a minute sample volume (50 micro-
liters), and rapid analysis. The presence of erythromycin in serum 
® 34 
samples will not interfere with the EMIT assay for theophylline. 
® 
The EMIT theophylline assay is designed to accurately quantitate theo-
phylline serum concentrations between 2.5 mcg/ml and 40 mcg/ml with 
a coefficient of variation of less than 10 percent within the thera-
peutic values of 10-20 mcg/ml. The only problems with this assay occur 
with severely hemolytic, lipemic, or icteric samples which can cause 
poor reproducibility and questionable quantitation. We did not encounter 
any^ such samples in our study. Theophylline controls were assayed 
along with the samples as part of the toxicology laboratory standard 
procedure. 
Statistical Analysis 
Data collected during the study was subjected to the Student's 
t-test for paired samples comparing the mean difference between the 
average of the two pre-erythromycin theophylline serum concentrations 
and the post-erythromycin theophylline serum concentrations. The con-
tributions of intrapatient variability and interpatient variability 
were determined by calculation of variance. 
RESULTS 
The data for the eleven patients in Phase I and the seven patients 
in Phase II are presented in Tables 1 through 4. There was no statis-
tically significant difference between the average of two pre-
erythromycin theophylline concentrations (samples A + B) and the post-
2 
erythromycin theophylline concentration (sample C) in Phase I or the 
samples C or D in Phase II. 
In order to appropriately calculate a statistically significant 
rise in the patients whose theophylline concentrations increased from 
baseline with erythromycin, it was necessary to first calculate the 
contribution of inherent intrapatient and interpatient variability. 
35 36 
The statistical model used and calculations are as follows: ' 
A) Inherent interpatient variability. 
d2 is based on the model 
E (y.., x = y + a. + 6.. + e. wijk) H l xj ljk 
where u, a., g.. are fixed variables, i i j 
i = 1, ... 18 subjects 
j = times A,B,C - Group I subjects 
times A,B,C,D - Group II subjects 
k = 1,2 duplicates 
a2 = Var (^j^) = variability due to duplicate measurements 
= variability due to laboratory and measurement error 
10 
SSE = z.z.l.  (y. M - y. .)2 
x j k xjk ij = (y., - y., )2/2 i J iJi ij 2 
= 20(0) + 20(Jg) + 9(2) + 4(9/2) + 1(8) + 2(12.5) 
= 79 
d2 = MSE = 79/56 = 1.4107 
B) Inherent intrapatient variability. 
d2. is based on the model J 
E(y. ) = ]i + a. + 3. . + e. .. wxjky K x xj ijk 
where y, a. are fixed variables, x 
Var (0. .) = a2. Var (e, .. ) = a2 ij J ijk 
i = 1, ... 18 subjects 
j = -£imes A,B (1 = A, 2 = B) 
k = 1,2 duplicates 
a2_. = variability due to duplicate baseline measurements 
= within - subject variability 
SSE (0. .) = Z.Z.Z, (Y.. - Y,)2 x j k w x j i 
= 2 .(y. - y, )2/2 where 1 = mean of A, 2 = mean of B x ±2 
= C7(.125) + 4(.5) + 1(1.125) + 4(3.125) + 1(4.5)12 
= 42 
MSE (g_) = 42/17 = 2.4706 
32. = h CMSE (e..) - a2: : 13 
= % (2.4706 - 1.4107) 
= 0.53 
Step A + Step B = total inherent variability due to interpatient and 
intrapatient variability 
= 1.94 
S.D. = 71.94 = 1.39 
Thus, the value of 3 mcg/ml may be defined as statistically 
significant. This represents 2.16 standard deviations, and it would 
be difficult to regard any change less than this as significant. 
On this basis, Table 2 reveals three patients in Phase I whose 
theophylline concentrations increased by 3.25, 6.20, and 6.50 mcg/ml 
after two days of erythromycin. In Phase II, Table 4 reveals that 
theophylline concentrations increased by 4.25 and 8 mcg/ml in each 
of two patients out of seven receiving four days of erythromycin. 
Howeverj none of the patients in Phase II demonstrated a statistically 
significant increase in theophylline concentration after seven days of 
erythromycin. The patient whose theophylline concentration was increased 
by 4.25 mcg/ml after four days of erythromycin did not maintain this 
increase after seven days of erythromycin. The type of theophylline 
product administered did not have any noticeable effect on whether or 
not a patient experienced an increase in theophylline concentration. 
An overall summary of these results is outlined in Table 5. 
Patients 2, 3, and 7 in Phase I were also patients 14, 13, and 15, 
respectively, in Phase II having been entered into the Phase II study 
at a later date. It was theorized that patients who did not demonstrate 
a significant increase in serum theophylline levels after two days might 
still demonstrate an increase if exposed to erythromycin for seven days. 
This did not occur in our three patients as shown in Table 6. None of 
12 
the patients in Phase I who experienced significant increases in serum 
theophylline concentration were restudied in Phase II. 
A degree of variability in five assays of the frozen duplicate samples 
* 
may be ascribed to the formation of a cryoprecipitate in our serum 
samples which was observed after thawing. This may have been due to the 
presence of fluoride in the vacuum tubes used to collect the samples. 
The presence of the cryoprecipitate may have caused falsely elevated or 
depressed readings of theophylline levels in the supernatant serum. 
None of the samples was significantly hemolyzed or lipemic, nor were any 
of the samples subjected to repeated freezing and thawing before analysis. 
Any of these factors may contribute to inaccuracies in the EMIT® assay and to 
the formation of a cryoprecipitate. We are currently unable to offer 
other axplanations for the occurrence of the cryoprecipitate in our 
frozen samples. 
DISCUSSION AND CONCLUSION 
The results of this controlled, prospective study demonstrated that 
not all patients will exhibit a predictable and statistically significant 
increase in serum theophylline concentrations after receiving oral 
erythromycin. 
Other published reports have demonstrated larger increases in 
theophylline concentrations with erythromycin than our study. Kozak 
31 
and Cummins, in a retrospective review, reported increases ranging from 
5 mcg/ml to as large as 15 mcg/ml in theophylline concentrations in 
C^ryoprecipitate is an insoluble complex formed by the precipita-
tion of fibrinogen and antihemophilic factor after fresh frozen plasma 
has been t h a w e d . 
13 
five pediatric patients. The authors subsequently initiated a pro-
spective study of 11 pediatric patients which demonstrated significant 
changes in theophylline concentrations (range 5.5 to 12 mcg/ml) in 
four out of eleven patients. None of the patients whose theophylline 
concentrations exceeded 20 mcg/ml were reported to have any signs or 
symptoms of theophylline toxicity. The authors concluded that the 
increases in theophylline concentrations occurred especially in those 
patients on high maintenance doses of theophylline, although the data 
were not entirely supportive of this conclusion. They also concluded 
that serum theophylline concentrations should be monitored in this 
high risk group when they are receiving erythromycin. However, flaws 
in the study, such as lack of control for intrapatient or interpatient 
variability, lack of compliance assessment, and incomplete inclusion 
of data for all patients in the study, make it difficult to draw any 
definite conclusions from these reports. In the present study, we could 
not identify any such high-risk group. The mean baseline theophylline 
concentration for the five patients whose concentrations increased 
significantly was approximately 11 mcg/ml, a concentration which is 
within therapeutic range. 
28 
Pfeifer et al published a prospective study in which nine healthy, 
young subjects (21 to 33 years old) received a single dose of intra-
venous aminophylline before and after challenge with erythromycin 250 mg 
every six hours for 48 hours. Although theophylline concentrations were 
not evaluated, these authors reported that two of the nine patients demon-
strated a decreased clearance of theophylline, and an increased serum 
half-life. These results closely coincide with our findings of increases 
14 
in serum concentration in three of eleven patients in Phase I. How-
ever, our study differed in that we used 500 mg doses of erythromycin 
for periods of 2, 4, and 7 days in elderly patients who had diagnosed 
chronic obstructive airways disease and were receiving oral maintenance 
theophylline. It would seem from the data in the present study that 
neither the dose nor the duration of erythromycin are factors which may 
be relied upon to cause predictable or dramatic increases of serum 
theophylline in patients receiving erythromycin. Since the patients par-
ticipated in the study for such a short period of time, they did not ab-
stain from xanthine containing foods or beverages and had not changed 
smoking habits in the recent past. These factors did not alter the 
overall results as compared to the data of Pfeifer, et al. 
Another interesting finding of the present study was that three 
patients in Phase I who did not demonstrate a significant increase in 
serum theophylline concentrations after two days could not be induced 
to demonstrate an increase after increased exposure to erythromycin of 
four and seven days. It appears that patients who do not demonstrate an 
increase in theophylline concentration within 48 hours will probably not 
demonstrate an increase with continued erythromycin therapy. 
The mechanism for the increase in theophylline concentration in patients 
receiving erythromycin has not been well described. Weinberger, et al27 
attributed the change in theophylline disposition with troleandomycin 
to a decreased theophylline elimination by either a decrease in hepatic 
uptake or alteration of metabolism by hepatic enzymes. Theophylline is 
39 40 
normally metabolized by three major pathways. ' It is 8-hydroxylated 
15 
to dimethyluric acid (DMU) by one form of cytochrome P450 or N-
demethylated to 3-methylxanthine (3-MX) or 1-methylxanthine (1-MX) 
by another form of cytochrome P450. One-methylxanthine is rapidly 
8-hydroxylated to 1-methyluric acid (1-MU) by xanthine oxidase. 
Since these metabolites can be measured in urine, future studies with 
erythromycin and theophylline measuring urinary theophylline metabo-
lites may help to clarify the mechanism by which erythromycin may 
alter the hepatic metabolism of theophylline. 
Another factor relating to metabolism of theophylline is the 
concept of non-linear elimination kinetics. This occurs due to partial 
or complete saturation of an elimination pathway,^ ^ and can result 
in a disproportionate rise in blood levels of theophylline as the dose 
is increased in some patients. However, perhaps this phenomenon is 
only exhibited in susceptible individuals. Whether or not these are 
the same individuals who will experience increases in theophylline 
concentrations after erythromycin due to saturation or competition for 
hepatic metabolism remains to be demonstrated. 
Even though this study demonstrated statistically significant increases 
in theophylline concentration in five out of eighteen patients, the 
clinical significance of our findings is more difficult to define. There 
are no criteria to identify the patients who will experience an increase 
in theophylline concentrations with erythromycin administration. One of 
our patients whose theophylline concentration after erythromycin increased 
to 21 mcg/ml experienced severe nausea and vomiting and was discontinued 
from the study. The other four patients whose theophylline concentrations 
16 
increased significantly after erythromycin did not experience any signs 
or symptoms of theophylline toxicity, perhaps due to the fact that 
theophylline concentrations did not increase into the toxic range (>20 
mcg/ml). All five patients with significantly increased theophylline 
concentrations had trough theophylline concentrations before erythro-
mycin ranging from 9.3 to 13 mcg/ml, well within therapeutic range. 
Therefore, some patients whose theophylline concentrations are within 
a safe therapeutic range may have the potential to develop toxicity 
after receiving erythromycin. 
Serum theophylline monitoring may not be required in all patients 
on theophylline preparations who concomitantly receive erythromycin, 
since the interaction appears to be idiosyncratic. However, the occasional 
patient-who begins to manifest symptoms of theophylline toxicity while 
on erythromycin may need monitoring of theophylline concentrations to 




































FIGURE 2. STUDY DESIGN - PHASE II 
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TABLE _1. Raw data from patients in Phase I. 
i 1 
SERUM THEOPHYLLINE CONCENTRATION (mcg/ml) 
i 
A B C 1 ! 
PATIENT NUMBER 1* 2 1 2 1 2 
1 10 ** ii ** 8 ** 
2 8 7 7 7 5 6 
1 
3 7 7 6 6 3 3 
1 
" 4 8 • 7 7 7 5 <2*** 1 I 
5 7 7 6 6 6 • ! 
6 11 7*** 12 11 13 14 
7 5 4 5 5 7 7 
8 11 11 10 10 17 17 
I 
9 8.2 10 10 9 14 1 7 ! 
10 13 16 12 12 16 14 
11 14 9*** ii 9 10 12 
D^uplicates of samples labeled A, B, or C are indicated by 1 and 2. 
**Data not available. 
***In the three cases where the concentration for duplicates was 
different than what should be attributed to laboratory error, 
the values were averaged for consistency of analysis. 
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TABLE 2. Phase I. Average theophylline concentrations before and after 
erythromycin and calculation of change in theophylline 
concentration after erythromycin. 
j I 
PATIENT NUMBER 
SERUM THEOPHYLLINE CONCENTRATION (mcg/ml) 
, 





10 11 8 10.5 1.0 -2.5 
1 
2 7.5 7 5.5 7.25 0.5 -1.75 
i 
3 7 6 3 6.5 1.0 -3.5 
4 7.5 7 5 7.25 0.5 -2.25 
i 
" 5 7 6 6 6.5 1.0 -0.50 
6 9 11.5 13.5 10.25 2.5 +3.25 
1 7 4.5 5 7 4.75 0.5 +2.25 
8 11 10 17 10.5 1.0 +6.50 
9 9.1 9.5 15.5 9.3 0.4 +6.20 




11.5 10 11 10.75 1.5 +0.25 
*The value for A, B, and C is the average serum concentration taken from 
one-half the sum of each of the duplicate measurements, 1 and 2, from 
Table 1. 
"^ Absolute value of the difference between the average of samples A and B. 
These values were used in calculation of intrapatient variability. 
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TABLE _3. Raw data from patients in Phase II. 
SERUM THEOPHYLLINE CONCENTRATIONS (mcg/ml) 
1 1 
i 
A B C D 
PATIENT NUMBER 1 2 1 2 1 2 1 2 
12 14 15 12 11 20 22 * 
— 
1 
13*** 12 11 10 11 10 9 10 io ! 
i 
14*** 14 14 14 13 11 10 13 ii 
15*** 9 8 11 11 11 10 15 10* 
16 12 14 11 14 16 15 14 15 
17 11 11 10 11 15 ** 12 14 ! 
18 7 9 6 5 7 7 8 8 
i 
*Patient 12 experienced severe nausea and vomiting and was discontinued 
from the study at day 4. 
**Sample not available. 
***Patients 2, 3, and 7 in Phase I were also patients 14, 13, and 15, 
respectively, in Phase II. 
AIn the one case where the concentration for duplicates was different 
than what should be attributed to laboratory error, the values were 
averaged for consistency of analysis. 
24 
TABLE _4. Phase II. Average theophylline concentrations before and after 
erythromycin and calculation of change in theophylline 
concentration after erythromycin. 
PATIENT NUMBER 
SERUM THEOPHYLLINE CONCENTRATION (mcg/ml) 
| 




12 14.5 11.5 21 — 13 3.0 +8.00 — 
13 11.5 10.5 9.5 10 11.0 1.0 -1.5 -1.0 
14 14 13.5 10.5 12 13.75 0.5 -3.25 -1.75 
15 8.5 11 10.5 12.5 9.75 2.5 +0.75 +2.75 
16 13 12.5 15.5 14.5 12.75 0.5 +2.75 +1.75 
17 11 10.5 15 13 10.75 0.5 +4.25 +2.25 
18 8 5.5 7 8 6.75 2.5 +0.25 +1.25 
1 
A^bsolute value of the difference between the average of samples A and B. 
These values were used in the calculation of intrapatient variability. 
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TABLE _5. Summary of results from Phase I and Phase II. 
Data should be read from left to right. 
Increased* No Change Decreased 
] 
Totals 
Phase I 2 days 3** 7 1 11 
Phase II 4 days 2 4 1 7 
7 days 0 7 0 6 
* Increase is defined as greater than 3.0 mcg/ml; decrease is defined 
as less than 3.0 mcg/ml; no change is defined as values between 
-3.0 and +3.0 mcg/ml. 
** Numbers in the tables refer to the number of patients. 
26 
TABLE 6_. Comparison of patients in Phase I after entrance into 
Phase II study. 
PHASE I RESULTS (mcg/ml) PHASE II RESULTS* (mcg/ml) 
PATIENT NUMBER A+B 2 
Net change 




Net change after 
erythromycin 
4 days 7 days 
2, 14 7.25 -1.75 13.75 -3.25 +1.75 
3, 
** 13 6.25 -3.5 11.0 -1.5 -1.0 
7, 15 4.75 +2.25 9.75 +0.75 +2.75 
T^rough theophylline concentrations were higher in Phase II since 




Bedside Recording Sheet 
Nurse's Information Sheet 
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PATIENT CHARACTERISTICS 
PATIENT NUMBER AGE THEOPHYLLINE PRODUCT DOSAGE REGIMEN 
1 55 Theodur® 400 mg bid 
2 62 Aminophyllin ® 200 mg q8h 
3 72 Choledyl® 200 mg q6h 
4 56 Theodur® 500 mg bid 
5 51 Theodur® 300 mg bid 
6 63 Aminophyllin ® 300 mg q6h 
7 62 Aminophyllin ® 300 mg q6h 
8 60 Aminophyllin ® 300 mg q6h 
9 54 Aminophyllin ® 400 mg q6h 
10 69 Aminophyllin ® 400 mg q6h 
11 82 Aminophyllin ® 200 mg q6h 
12 66 Theodur® 300 mg tid 
13 72 Aminophyllin ® 400 mg q6h 
14 62 Aminophyllin ® 300 mg q6h 
15 62 Aminophyllin ® 400 mg q6h 
16 73 Aminophyllin. ® 300 mg q6h 
17 80 Aminophyllin ® 500 mg q6h 
18 71 Theodur® 400 mg bid 
THE EFFECTS OF ORAL ERYTHROMYCIN ON SERUM CONCENTRATIONS OF 
THEOPHYLLINE IN PATIENTS WITH CHRONIC OBSTRUCTIVE LUNG DISEASE 
CONSENT FORM 
We are conducting a study to see if the antibiotic, erythromycin, 
will raise the blood level of theophylline in people who take theophylline 
daily for certain lung diseases. Theophylline is a drug which widens 
airways and helps breathing. It is important for us to find out if 
theophylline levels increase, since high levels of this drug will make 
it necessary to decrease the dose of theophylline. 
The study will involve our taking approximately four to six blood 
samples from a vein. Each sample will be no more than 5 mis (1 teaspoon-
ful) and will be used to measure the level of theophylline in your 
blood at various times. There will be some discomfort from blood 
drawing and a small amount of blood loss from this procedure. You will 
also be asked to take, by mouth, a total of either four or eight doses 
of erythromycin over 2 or 7 days to see what effect it has on your 
theophylline blood levels. All the doses you will receive are normal 
recommended adult doses. Although erythromycin may cause an upset 
stomach, loose stools, or rashes, it is unlikely that you will have 
any of these reactions. 
The information we will find out from this study may help you in 
the future if you need to take erythromycin for an infection. Also, 
this study is of no charge to you as a participant. 
Any questions you may have during this study will be gladly and 
promptly answered by any of the investigators. You are free to withdraw 
your consent and be discounted from the study at any time you desire 
without any ill consequences. 
Medical treatment or compensation for physical injury: 
In the event you sustain physical injury resulting from the 
research project in which you are participating, the University of Utah 
will provide you, without charge, emergency and temporary medical treat-
ment not otherwise covered by insurance. Furthermore, if your injuries 
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are caused by negligent acts or omissions of University employees 
acting in the course and scope of their employment, the University may 
be liable, subject to limitations prescribed by law, for additional 
medical costs and other damages you sustain. If you believe that you 
have suffered physical injury as a result of participation in this 
research program, please contact the Office of Research Administration, 
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NURSING INFORMATION SHEET 
STUDY TITLE: Effect of erythromycin on serum levels of theophylline. 
PURPOSE: To determine if erythromycin will increase serum 
levels of theophylline. 
STARTING DATE:August 18, 1980 
INVESTIGATORS:Barry Stults, M.D. 
June Felice-Johnson, Pharm D Candidate 
Martin Higbee, Pharm D 
Ken Hardigan, M.D. 
Ross Morgan, M.D. 
PATIENTS: Males with chronic obstructive airways disease who are 
on chronic theophylline therapy. 
NURSING RESPONSIBILITIES: 
1. Administration of oral erythromycin stearate (Abbott) 500mg 
every six hours for 2 to 7 days as ordered by investigator or 
housestaff. 
2. Administration of an oral theophylline product as ordered by 
housestaff or investigator. 
3. Recording on bedside sheet marked "STUDY PATIENT" of medication 
administered and time. 
NOTE: Blood draws are the responsibility of the study investigators. 
It is very important that doses of erythromycin and theophylline 
be administered at the scheduled time since blood draws will be 
scheduled for specific times after administration of doses. 
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